Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial

Abstract

Tofacitinib is an oral Janus kinase inhibitor. These post‐hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52‐week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo‐treated patients advanced to tofacitinib at week 16. Primary efficacy end‐points were the proportions of patients with 75% or more reduction from baseline Psoriasis Area and Severity Index (PASI‐75) and Physician's Global Assessment (PGA) of “clear” or “almost clear” (PGA response) at week 16. Other end‐points included: Itch Severity Item (ISI), Dermatology Life Quality Index (DLQI) score and Nail Psoriasis Severity Index (NAPSI). Adverse events (AEs) were recorded throughout the study. Overall, 58 Japanese patients were included in this analysis (tofacitinib 5 mg b.i.d., n = 22; 10 mg b.i.d., n = 24; placebo, n = 12); 29 completed the study. At week 16, significantly more patients receiving tofacitinib 5 and 10 mg b.i.d. versus placebo achieved PASI‐75 (50% and 75% vs 0%, P < 0.01) and PGA response (59% and 75% vs 0%, P < 0.001). Substantial improvements in ISI, DLQI and NAPSI score were observed with both tofacitinib doses. Over 52 weeks, similar rates of AEs were reported across treatment groups; one serious AE occurred with tofacitinib 10 mg b.i.d. Herpes zoster occurred in three patients receiving tofacitinib 10 mg b.i.d. No deaths, serious infections, malignancies or gastrointestinal perforations were reported. Results were generally consistent with global analysis, suggesting sustained efficacy and a manageable safety profile, with increased herpes zoster incidence, of tofacitinib in Japanese patients with psoriasis.

<p>Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives</p>

“…Tofacitinib 10 mg was found to be non-inferior to etanercept, but tofacitinib 5 mg was not shown to be non-inferior to etanercept. 32 Although study results demonstrated that both the 5 mg and 10 mg doses were effective in treating plaque psoriasis, [33][34][35] the 10 mg dose was proven to be more efficacious. 36 However, this higher dose is associated with increased safety concerns, leading the FDA to decline approval of tofacitinib for moderate-to-severe plaque psoriasis.…”

Small Molecules and Biologics in the Treatment of Nail Psoriasis

“…NAPSI scores continued to decrease through week 52 in both tofacitinib dose groups. By week 52, 22.2 and 47.6% of the patients who received tofacitinib 5 and 10 mg, respectively, achieved NAPSI 75 [19]. Adverse events most commonly related to laboratory parameter abnormalities were noted.…”

Successful use of Netakimab in the treatment of psoriasis accompanied by the psoriatic onychodystrophy

“…На 16-й нед. значительно больше пациентов, получавших тофацитиниб по сравнению с плацебо, достигли NAPSI 50 (32,8,44,2 против 12,0%), NAPSI 75 (16,9, 28,1 против 6,8%) [30,31].…”